货号：DT2025061505
CAS：1002345-93-8
规格：mg(更多包装需求请咨询客服)
纯度：≥98%
生产商：试剂家

生物活性：Lovastatin-d3 is deuterium labeled Lovastatin. Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Lovastatin-d3 相关抗体:
HMGCS2 Antibody
Ferritin Heavy Chain Antibody
HMGB1 Antibody
AMID/FSP1 Antibody
Peroxiredoxin 1 Antibody (YA692)
PRDX3 Antibody (YA909)
HMGCR Antibody
Baf180 Antibody (YA1176)
BANF1 Antibody (YA1740)
LEF1 Antibody (YA3164)
Ferritin Light Chain Antibody (YA971)
Ferritin Light Chain Antibody (YA972)
HMGA1 Antibody (YA1185)
HMGA2 Antibody (YA1186)
Baf57 Antibody (YA2110)
HMGN2 Antibody (YA2839)
HMG4 Antibody (YA2992)
HMGB2 Antibody (YA2995)
HMGCL Antibody (YA3024)
分子量：407.56
Formula：C24H33D3O5
CAS 号：1002345-93-8
非标记 CAS：75330-75-5
中文名称：洛伐他汀-d3； 辛伐他汀EP杂质E-d3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (531 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Alberts AW, et al. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988 Nov 11;62(15):10J-15J.
 [Content Brief]
[3]. Kah J, et al. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep. 2012 Sep;28(3):1077-83.
 [Content Brief]
[4]. Frishman WH, et al. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am. 1989 Mar;73(2):437-48.
 [Content Brief]
[5]. Tobert JA, et al. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.
 [Content Brief]
[6]. Ifergan I, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006 Jul;60(1):45-55.
 [Content Brief]